Posts by: Leonor Mateus Ferreira

Leonor Mateus Ferreira

Leonor Mateus Ferreira is an emerging, young journalist, with a Batchelor's degree in Communication and post-graduate degree in Multiplatform Journalism. She is particularly interested in politics and current affairs, and is currently studying for a masters degree in economics and public policies.

January 7, 2015November 5, 2015

KaloBios’ Pseudomonas Aeruginosa Lung Infection Therapy Fails Study Primary Endpoint in CF Patients

Cystic Fibrosis, News

KaloBios Pharmaceuticals, Inc. announced that its potential treatment for Pseudomonas aeruginosa (Pa) lung infections was unable to meet the primary endpoint — “increased time to need for antibiotics for worsening respiratory tract ... Read more

January 7, 2015January 7, 2015

Working Night Shift May Increase Lung Cancer and CVD Mortality

Lung Cancer

Working night shifts for extended periods of time increase mortality related to the development of lung cancer and cardiovascular disease (CVD), particularly among women, according to study recently published at the American Journal ... Read more

January 6, 2015November 5, 2015

Shire Presents Novel CF Drugs to Investors at R&D Day

Cystic Fibrosis

Shire has organized a Research and Development (R&D) Day specially designed to present the company’s latest medications for the treatment of rare diseases and other conditions, including cystic fibrosis (CF), to the investment ... Read more

December 31, 2014November 11, 2015

Actelion Submits New Drug for Pulmonary Arterial Hypertension to FDA

News, Pulmonary Hypertension

Actelion has submitted its new treatment for pulmonary arterial hypertension (PAH) to the U.S. Food and Drug Administration (FDA). The company is applying for a New Drug Application (NDA) for selexipag (Uptravi), after having ... Read more

December 30, 2014November 5, 2015

FDA Approves Kalydeco for Cystic Fibrosis Patients with R117H Mutation

Cystic Fibrosis, News

The U.S. Food and Drug Administration (FDA) has approved the prescription of Kalydeco (ivacaftor) for the treatment of cystic fibrosis (CF) patients 6 years and older with the R117H mutation in the ... Read more

December 29, 2014November 5, 2015

Medtronic Submits Drug Delivery System to FDA to Complement United Therapeutics’ PAH Treatment

News, Pulmonary Hypertension

Medical technology developer Medtronic, Inc. recently completed an application submission to the U.S. Food and Drug Administration (FDA) regarding the pre-market approval of their SynchroMed II implantable drug infusion system, which includes a new catheter design. The ... Read more

December 29, 2014November 6, 2015

U.S. Environmental Agency Grants $4.5 Million to Improve Indoor Air Quality, Reduce Lung Diseases Like Asthma

Asthma, News

The U.S. Environmental Protection Agency (EPA) has announced the funding of eight grants which will be awarded to U.S.-based organizations as a way of promoting public health through the reduction the exposure to indoor ... Read more

December 26, 2014November 5, 2015

Galapagos Begins Phase I Study For Novel Cystic Fibrosis Therapy

Cystic Fibrosis, News

Developmental stage Galapagos NV is initiating its first phase 1 study to evaluate a CFTR targeted therapy for the treatment of cystic fibrosis (CF) called GLPG1837. The company is assessing a novel ... Read more

December 22, 2014December 22, 2014

Gaps in Knowledge about Lung Cancer Identified in French Population

Lung Cancer, News

There are still several fears and misconceptions among the French population regarding lung cancer, according a prospective survey conducted nationwide on perceptions about the disease. While the study was conducted in France ... Read more